Avidian Wealth Enterprises LLC Acquires 1,698 Shares of Johnson & Johnson (NYSE:JNJ)

Avidian Wealth Enterprises LLC increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,790 shares of the company's stock after acquiring an additional 1,698 shares during the quarter. Avidian Wealth Enterprises LLC's holdings in Johnson & Johnson were worth $3,116,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. MRP Capital Investments LLC increased its holdings in Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after acquiring an additional 65 shares during the last quarter. Syverson Strege & Co boosted its position in Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after purchasing an additional 65 shares during the period. Sage Mountain Advisors LLC increased its stake in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after purchasing an additional 67 shares in the last quarter. Sovereign Financial Group Inc. raised its position in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after purchasing an additional 69 shares during the period. Finally, Almanack Investment Partners LLC. lifted its stake in shares of Johnson & Johnson by 1.1% during the 1st quarter. Almanack Investment Partners LLC. now owns 6,633 shares of the company's stock valued at $1,100,000 after buying an additional 71 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on JNJ shares. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Barclays dropped their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Morgan Stanley lifted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Trading Up 0.1%

Shares of Johnson & Johnson stock opened at $152.58 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a market cap of $367.12 billion, a PE ratio of 16.97, a PEG ratio of 2.31 and a beta of 0.42. The company has a 50 day simple moving average of $153.66 and a two-hundred day simple moving average of $153.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. Johnson & Johnson's dividend payout ratio is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.